Overview

A Study of LY3522348 in Healthy Participants

Status:
Completed
Trial end date:
2021-08-17
Target enrollment:
Participant gender:
Summary
The main purpose of this study in healthy participants is to learn more about the safety of LY3522348 and any side effects that might be associated with it. Blood tests will be performed to check how much LY3522348 gets into the bloodstream and how long it takes the body to eliminate it. This study has two parts: Part A will last up to about six weeks and Part B will last up to about eight weeks for each participant.
Phase:
Phase 1
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Midazolam